Related Experiment Videos
Adjuvant interferon for anal condyloma. A prospective, randomized trial
1Division of Colon and Rectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
Diseases of the Colon and Rectum
|December 1, 1994
Summary
Adjuvant interferon alfa-n3 therapy significantly reduced anal condyloma recurrence after surgery. This treatment shows promise for preventing condyloma regrowth in patients, especially those with persistent or specific HPV types.
Area of Science:
- Dermatology
- Virology
- Surgical Oncology
Background:
- Anal condyloma (genital warts) frequently recurs after surgical removal.
- High recurrence rates necessitate improved treatment strategies to prevent disease persistence.
Purpose of the Study:
- To evaluate the efficacy of interferon alfa-n3 as an adjuvant therapy to surgical excision and fulguration for anal condyloma.
- To determine if interferon can reduce the recurrence rate of anal condyloma post-surgery.
Main Methods:
- A prospective randomized study involving 43 patients with anal condyloma.
- Group I (n=25) received surgical treatment followed by interferon alfa-n3 injections.
- Group II (n=18) received surgical treatment followed by saline injections as a control.
Main Results:
- Recurrence rates were 12% in the interferon group versus 39% in the saline group (P=0.046).
- Interferon was more effective in patients with condylomata present for over six months (P=0.04).
- Treatment showed efficacy in patients with human papillomavirus DNA subtypes 6/11 (P=0.05).
Conclusions:
- Adjuvant interferon alfa-n3 therapy significantly decreases the recurrence rate of anal condyloma after surgical extirpation.
- Interferon is a viable option for reducing condyloma recurrence, particularly in specific patient subgroups.